Oral Mucosal Effects In Adult Smokers Associated With Two Nicotine Lozenge Formulations
Randomized, Parallel-Group, Assessor Blind Study To Evaluate Oral Mucosal Effects In Healthy Adult Smokers Associated With 3 Week Use Of Nicotine Bi-tartrate 4mg Mint Lozenges Relative To The Use Of Nicotine Polacrilex 4mg Mint Lozenges
Sponsor: Inflamax Research Incorporated
This PHASE1 trial investigates Safety Issues and is currently completed. Inflamax Research Incorporated leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Feb 2021 — Jul 2024 [monthly]
Completed PHASE1
Status: Unknown Status → Completed · Phase: PHASE3 → PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Unknown Status PHASE3
-
Oct 2019 — Jan 2021 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Oct 2019 [monthly]
Active Not Recruiting PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2017 — Oct 2017 [monthly]
Recruiting PHASE3
First recorded
Mar 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Inflamax Research Incorporated
- Niconovum USA
For direct contact, visit the study record on ClinicalTrials.gov .